Canton Hathaway’s VanEck Pharmaceutical ETF PPH Stock Holding History

Canton Hathaway’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Hold	10,000	–	–	0.21%	59
2026 Q1	$1.04M	Hold	10,000	–	–	0.21%	60
2025 Q4	$1.03M	Hold	10,000	–	–	0.2%	61
2025 Q3	$904K	Hold	10,000	–	–	0.17%	64
2025 Q2	$880K	Hold	10,000	–	–	0.18%	62
2025 Q1	$911K	Buy	+10,000	New	+$901K	0.18%	56

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Canton Hathaway's PPH Position: Q2 2026 in Review

Canton Hathaway held its VanEck Pharmaceutical ETF (PPH) position steady in Q2 2026 at 10,000 shares worth $1.09M. The position accounts for 0.21% of the portfolio, ranked #59.

Canton Hathaway first reported a position in PPH in Q1 2025 and has held it in 6 quarters since. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Canton Hathaway held 10,000 shares of VanEck Pharmaceutical ETF worth $1.09M as of Q2 2026.
Canton Hathaway left its VanEck Pharmaceutical ETF share count unchanged in Q2 2026.
VanEck Pharmaceutical ETF made up 0.21% of Canton Hathaway's portfolio in Q2 2026, its #59 holding.
Canton Hathaway first reported a position in VanEck Pharmaceutical ETF in Q1 2025 and has held it in 6 quarters since.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Canton Hathaway's 13F filing for Q2 2026, filed 6 Aug 2026.